Kindstar Sets March 27 Board Meeting to Approve 2025 Results and Consider Final Dividend

Kindstar Globalgene Technology, Inc. ( (HK:9960) ) has issued an announcement.

Kindstar Globalgene Technology, Inc. has scheduled a board meeting for March 27, 2026, to review and approve the group’s consolidated final results for the financial year ended December 31, 2025, and to authorize their publication. The board will also consider whether to recommend a final dividend for the year and may address other corporate matters, signaling upcoming disclosures that could influence shareholder returns and market expectations.

The announcement also confirms the current composition of the company’s board, listing its executive, non-executive, and independent non-executive directors, which underscores the firm’s established governance structure. This governance disclosure provides investors with clarity on oversight as the company approaches a key financial reporting milestone and evaluates potential capital allocation decisions, including any dividend proposal.

The most recent analyst rating on (HK:9960) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Kindstar Globalgene Technology, Inc. stock, see the HK:9960 Stock Forecast page.

More about Kindstar Globalgene Technology, Inc.

Kindstar Globalgene Technology, Inc. is a Cayman Islands–incorporated company listed in Hong Kong that operates through a group structure. It is active in the healthcare and biotechnology sector, focusing on specialized medical and genetic testing services in mainland China and related markets. The group is overseen by a board comprising executive, non-executive, and independent non-executive directors.

Average Trading Volume: 665,080

Technical Sentiment Signal: Sell

Current Market Cap: HK$1.25B

For a thorough assessment of 9960 stock, go to TipRanks’ Stock Analysis page.